Prevnar 13 regulatory update

The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) recommended the use of Pfizer's Prevnar 13 for adults >=19 years with immunocompromising conditions, including those with functional or anatomic asplenia, HIV infection, cancer or advanced kidney disease. Pfizer said there are no data on the safety or effectiveness of Prevnar 13 in immunocompromised patients; the pharma expects to report data from clinical studies in the population by year end or early next year. ...